Cough adverse events and FVC decline in the ATLAS study of inhaled pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis - Vienna 2024

Advancing clinical trials and care in pulmonary fibrosis

Chair(s): Vivien Somogyi, Yet Hong Khor

Session type: Poster session

Cough adverse events and FVC decline in the ATLAS study of inhaled pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis

Nazia Chaudhuri

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy

Tsuyoshi Sasada

Poster

Abstract

International survey on Current Standards for Immunosuppression in Fibrosing Interstitial Lung Diseases

Manuela Funke-chambour

Poster

Abstract

Impact of Air Pollution on Hospitalizations in Patients with Idiopathic Pulmonary Fibrosis in the Community of Madrid

Pablo Mariscal Aguilar

Poster

Abstract

Nutritional assessment of patients with Idiopathic pulmonary fibrosis and nutritional supplements

Javier L?pez

Poster

Abstract

Use of telomere length in the management of idiopathic pulmonary fibrosis

Caroline Dahlqvist

Poster

Abstract

Nutritional assessment as a predictor of mortality in idiopathic pulmonary fibrosis

Daniel Enrique Vega Lizarazo

Poster

Abstract

Understanding intentional and non-intentional non-adherence in Pulmonary Fibrosis to antifibrotic treatment: a patient-led multivariate analysis

Steve Jones

Poster

Abstract

Cough adverse events and FVC decline in the ATLAS study of inhaled pirfenidone (AP01) in Idiopathic Pulmonary Fibrosis

Nazia Chaudhuri

Poster

Abstract

COMPANION - a randomised controlled study to evaluate the impact of a digital therapy on anxiety and quality of life in patients with pulmonary fibrosis

Cecilia Ganslandt

Poster

Abstract

Determinants of cough related quality of life in interstitial lung diseases

Eeva Saari

Poster

Abstract

Acute exacerbation of Interstitial Lung Disease specific comorbidity Index (AEILD-CI) to assess the risk of in-hospital death: a prospective cohort study

Xin Zhang

Poster

Abstract

Baseline characteristics of patients enrolled in the FIBRONEER-ILD trial of nerandomilast (BI 1015550)

Toby M Maher

Poster

Abstract

Design of the FIBRONEER-ON open-label extension trial of nerandomilast (BI 1015550)

Wim A. Wuyts

Poster

Abstract

Changes in lung function and mortality risk in patients with idiopathic pulmonary fibrosis (IPF)

Divya Patel

Poster

Abstract

Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references

Claudia Valenzuela

Poster

Abstract

Enhancing clinical trials design by involving and integrating patient-input through a novel approach: Human factors Clinical Study Experience Simulation

Marta Lombardini

Poster

Abstract

The Long-Term Prognostic Impact of Clinical Frailty Scale on Acute Exacerbation of Fibrotic Interstitial Lung Disease

Shoichiro Saito

Poster

Abstract

Analysis of Nintedanib Dosing and Mortality in US Medicare Data

Andrew H. Limper

Poster

Abstract

Trastuzumab Deruxtecan (T-DXd)-associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies.

Lana Elu

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}